Abstract:Apatinib is a tyrosine kinase inhibitor which selectively inhibits VEGFR-2 and also represents mild inhibition to PDGFR, c-Kit and c-src. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis and tumor cell proliferation. Previous clinical trials have demonstrated its obvious antitumor activity in various cancer type. Thus we designed this phase II, open-label, single-armed, prospective study (NCT02515435) to investigate the efficacy and safety of apatinib for heavily treated, advanced non-squamous NSCLC patients who are not applicable to current standardized therapy or other clinical trials. We prospectively enrolled 40 patients with previously heavily treated advanced non-squamous NSCLC. All patients received apatinib with a dose of 500mg, q.d., p.o. Efficiency was evaluated initially 4 weeks later and then every 8 weeks until disease progression, death, or unacceptable toxicity. The primary end point of this study was overall response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS). Forty patients were enrolled in the study with a median age of 61. 15% of patients received apatinib as second-line therapy, 40% of patients received apatinib as third-line therapy, and 60% as forth-line to twelfth-line therapy. Nine patients were found with activated EGFR mutation. Among all the enrolled patients, 38 patients had clinical evaluation and the other 2 received treatment of apatinib less than one month. Within 33 patients who had available image efficiency, 6 were identified as PR,17 SD and 10 PD, no CR was observed. The ORR was 18.18 %, the DCR was 69.69%. The ORR for patients with EGFR mutation positive and negative were 25% and 16% separately. The median PFS was 3.22 months (95% CI, 2.20-4.17 months). Among them, 6 patients received the treatment of apatinib more than five months. The 6-month OS rate was 76.98% (95% CI, 61.68%-92.27%), the 12-month OS rate was 57.48% (95% CI, 28.75%-86.20%). Common treatment-related adverse events were proteinuria (25%), hypertension (17.5%), and hand-foot-skin reaction (HFSR)(27.5%). Severe adverse events included grade 3 hypertension (5%), HFSR (5%), and thrombocytopenia (5%), no grade 4 or 5 adverse events were observed. No un-expected adverse events were found. Apatinib as a monotherapy had a promising overall response together with an acceptable side effect in patients with previously heavily treated advanced non-squamous NSCLC. A phase III study comparing apatinib monotherapy with placebo as 3rd/4th setting in advanced non-squamous NSCLC is ongoing to further evaluated the efficacy of apatinib (NCT02332512).

A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer

P1.12-01 A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC after Second/Third-Line Chemotherapy

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results from a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial.

P3.01-085 A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression

Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study

A Phase II, Multicenter, Placebo-Controlled Trial of Apatinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) after Two Previous Treatment Regimens.

Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment.

Efficacy and Safety of Apatinib in Patients with Previously Treated Metastatic Colorectal Cancer: a Real-World Retrospective Study

Clinical Study on the Efficacy of Apatinib Treatment for Advanced Ovarian Cancer after Second-Line Chemotherapy Failure

Apatinib Combined with Raltitrexed in Patients with Metastatic Colorectal Cancer after Failure of Standard Therapy (AHEAD-311): A Single-Arm Phrase II Pilot Trial.

A Pilot Study of Apatinib As Third-Line Treatment in Patients with Heavily Treated Metastatic Colorectal Cancer

Multicenter Phase II Study of Apatinib Treatment for Metastatic Gastric Cancer after Failure of Second-Line Chemotherapy.

A Randomized, Double-Blind, Multicenter, Phase Ii, Three-Arm, Placebo-Control Study of Apatinib As Third-Line Treatment in Patients with Metastatic Gastric Carcinoma.

Exploration of Patients with Gastric Cancer Who Benefit from Apatinib: an Updated Real-World Study.

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib's Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion

Basket Trial in Advanced Cancers: A Clinical Observation of Apatinib in Lung Metastases and Non-Lung Metastases

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study.

Apatinib As Third-Line or Beyond Therapy in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: an Open-Label, Multicenter, Post-Marketing Phase IV Study (Ahead-G201)